

Accepted Manuscript

Title: Consolidation Therapy for Newly Diagnosed Pediatric High-Risk Neuroblastoma Patients Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplant, Anti-GD2 Antibody, GM-CSF, IL-2 and Haploidentical NK Cells

Author: Aimee C. Talleur, Brandon M. Triplett, Sara Federico, Ewelina Mamcarz, William Janssen, Jianrong Wu, David Shook, Wing Leung, Wayne L. Furman

PII: S1083-8791(17)30581-5
DOI: <http://dx.doi.org/doi: 10.1016/j.bbmt.2017.07.011>
Reference: YBBMT 54734


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 10-5-2017

Accepted date: 12-7-2017

Please cite this article as: Aimee C. Talleur, Brandon M. Triplett, Sara Federico, Ewelina Mamcarz, William Janssen, Jianrong Wu, David Shook, Wing Leung, Wayne L. Furman, Consolidation Therapy for Newly Diagnosed Pediatric High-Risk Neuroblastoma Patients Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplant, Anti-GD2 Antibody, GM-CSF, IL-2 and Haploidentical NK Cells, *Biology of Blood and Marrow Transplantation* (2017), <http://dx.doi.org/doi: 10.1016/j.bbmt.2017.07.011>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Consolidation therapy for newly diagnosed pediatric high-risk neuroblastoma patients using busulfan/melphalan, autologous hematopoietic cell transplant, anti-GD2 antibody, GM-CSF, IL-2 and haploidentical NK cells

Aimee C. Talleur¹, Brandon M. Triplett¹, Sara Federico², Ewelina Mamcarz¹, William Janssen¹, Jianrong Wu³, David Shook¹, Wing Leung¹ and Wayne L. Furman²

¹Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee

²Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee

³Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee

Key Words: GD2 monoclonal antibody; neuroblastoma; autologous transplant; immunotherapy; NK cells

Running title: Combination therapy for pediatric high-risk neuroblastoma

Corresponding author:

Wayne L. Furman

262 Danny Thomas Place, Mailstop 260, Memphis TN 38105

Phone 901-595-3300

Fax 901-595-2220

Wayne.furman@stjude.org

Funding sources: This work was supported by the St. Jude Children's Research Hospital Comprehensive Cancer Center Support Grant (2 P30 CA021765), American Lebanese Syrian Associated Charities, Cookies for Kids' Cancer and Cure Childhood Cancer Foundation

Financial Disclosure statement: The authors have no financial disclosures.

Conflict of Interest statement: The authors have no conflicts of interest to disclose.

Download English Version:

<https://daneshyari.com/en/article/8430806>

Download Persian Version:

<https://daneshyari.com/article/8430806>

[Daneshyari.com](https://daneshyari.com)